Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized multicenter investigator-sponsored Phase 2 trial evaluating MaaT033 concomitant to anti-PD1 treatment in advanced lung cancer patients

Next Previous
Trial Profile

A randomized multicenter investigator-sponsored Phase 2 trial evaluating MaaT033 concomitant to anti-PD1 treatment in advanced lung cancer patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MaaT 033 (Primary)
  • Indications Lung cancer; Non-small cell lung cancer
  • Focus Therapeutic Use

Most Recent Events

  • 19 Jun 2025 According to MaaT Pharma media release, this trial is expected by the sponsor to start mid-2025.
  • 12 May 2025 According to MaaT Pharma media release, an external Scientific Advisory Committee took place at the end of March 2025 to review the full data from IASO trial and provided insights regarding the best population to target in a Phase 2 trial.
  • 17 May 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top